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Background
qPCR functions by generating a fluorescent reading with every cycle,
which increases exponentially in line with the quantity of DNA present
in each well. Generally, qPCR instruments report back the cycle number
at which fluorescence first becomes significantly different from the
background (variously referred to as Cq, Ct or Cp). This is then used 
to calculate the concentration of the starting mRNA in the sample 
by comparison to a standard curve or in calculation of the value 
of ΔΔCt to determine relative changes in expression of a gene 
(see 2 for explanation). 
Although this is essentially straightforward, it is in fact often over-
simplified and care is required in all aspects of sample preparation,
storage of both samples and reagents, both design and verification of
PCR assays and appropriate assessment of normalisation procedures to
The process of amplifying DNA by exploiting the polymerase chain reaction (PCR) was first reported in the 1980s by
Mullis and colleagues1. This formed the basis for the next step of PCR technology: using dyes to quantify the amount
of DNA being produced after each cycle of the reaction. This process became known as quantitative real-time PCR
(qPCR) and has been extensively used to assess the expression of genes from a huge variety of species, becoming a
fundamental tool in investigative studies within molecular biology. Here, we discuss the use of qPCR to assess the
differentiation of hepatic cell models at an early stage to inform model selection for drug development uses.
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ensure high quality data are produced. Without this verification, the
end results can be at best disappointing and at worst entirely
misleading. This is an area that needs recognition and significant
improvements if qPCR studies are to have relevance in scientific
reporting. The publication of inaccurate data due to elementary
mistakes can and possibly has damaged the reputation of this
technique for producing reliable and repeatable data. This was 
critically recognised by Steve Bustin and
colleagues3, who published the Minimum
Information for Publication of Quantitative
Real-Time PCR Experiments (MIQE) guide lines
in an attempt to improve qPCR standards. 
This provides a basic set of requirements for
producing a reliable and repeatable qPCR assay
to improve the quality of data reported. This is particularly important
when qPCR data are being collated from the literature and used in
comparisons, such as in the assessment of tissue responses to
challenge or treatment in a variety of cell lines, or in the preliminary
assessment of a model. 
The search for appropriate cell lines
Drug development is an expensive process, especially considering the
fact that a compound can pass through initial tests unscathed but then
produce toxic effects in later studies or even in patients. The cost of
bringing a drug to market has been esti-
mated to be $800 million to $2 billion4,5
so any improvement in the process of testing
novel compounds to yield more reliable, rele -
vant data in terms of predicting effects in
patients would be of enormous benefit both 
to patients and in reducing costs overall. 
The liver plays a critical role in drug metabolism and excretion in the
body and so, currently, the gold standard model for in vitro testing of
novel compounds is the primary hepatocyte. These are isolated directly
from human liver and used within a short
time frame to provide the most relevant data
currently possible from a cell model.
However, together with the moral and ethical
dilemmas of using such tissue, consistent
and reliable supply can be an issue since the
cells must be used within a short time frame
to minimise de-differentiation away from the
true in vivo hepatic phenotype. Primary
hepatocytes are therefore a costly model to
use and not ideally suited to initial high-
throughput drug discovery phases. Although
there are other systems such as cryo -
preserved hepatocytes available, there
continues to be a search for cell lines which
could reliably predict toxicity and drug-drug
interactions, with the potential to cut the
costs of drug development dramatically. 
Cell lines are relatively cheap and easy to
maintain but do have their drawbacks. Well
established hepatocyte-like or hepatocyte-
derived cell lines such as HepG2 have been
shown to differ markedly from the in vivo
hepatocyte. This is especially evident in
expression of metabolising enzymes like the
cytochrome P450 (CYP) family, some of which
are particularly important in drug metab -
olism6-11. A fairly recently established cell line,
HepaRG, is potentially phenotypically much
closer to the in vivo hepatocyte12-16. Further
hepatocyte-like differentiation may be
achieved by treatment with dimethyl
sulphoxide (DMSO), which is also used in
maintaining the differentiated state of
isolated primary hepatocytes17. 
Hepatic cell line experiment
Here, we investigated DMSO treatment of
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Figure 1: Development of a qPCR assay for albumin. Part (a) shows primer and exon locations, melting temperature
and product length, with endpoint PCR results shown in part (b). Part (c) shows sequencing results for the product. Data
concerning the qPCR assay are shown in parts (d) and (e), where melt peaks, the corresponding melting temperatures
and standard curve information are displayed
Currently, the gold standard model
for in vitro testing of novel compounds is
the primary hepatocyte
two other established hepatocyte-derived human cell lines, HepG2 and
Huh7. qPCR was used to assess expression of a variety of genes in
relation to in vivo levels, which was then compared to available data
from the literature for HepaRG cells. 
HepG2 and Huh7 cells were grown on six-well plastic plates in
normal growth media until roughly 90% confluent and subsequently
treated with 1% DMSO (v/v) for up to 30 days. Initial expression data for
markers of differentiation indicated an optimal exposure period of 15
days, which was used for all subsequent experi ments. RNA was then
extracted (SV Total RNA Isolation System, Promega), the quality
assessed (2100 Bioanalyser, Agilent, California, USA), reverse
transcribed (MMLV Reverse Transcriptase and RNasin, Promega), and
qPCR performed for a range of genes (LightCycler 480, Roche). Sample
quality is a key factor in the success of qPCR and in all experiments only
RNA with a RIN of greater than eight was used.
Assay design and validation, as noted earlier, is vital in obtaining
accurate and reliable qPCR data. Figure 1 (page 9) illustrates the process
of validation carried out for an albumin qPCR assay using Sybr green as
the DNA marker; the process is essentially similar for each qPCR assay.
Albumin is illustrated as a recognised marker of adult human
hepatocyte differentiation. Primers were designed so that one of the
pair crosses an exon-exon boundary, to remove the possibility of
amplifying any contaminating genomic DNA, and total product length
was under 150 base pairs where possible to ensure maximum PCR
efficiency (Figure 1a, page 9). HPLC purification of primers can increase
the accuracy of an assay where standard desalting purification results
in an assay containing multiple products. Initially, the primers were
used to conduct an end point PCR, analysed by agarose gel
electrophoresis (Figure 1b, page 29), to ensure that only one product
was generated and to identify the presence or not of primer dimers.
The products were extracted from the agarose gel and cloned using the
pGEM T-easy vector system (Promega). This allowed both sequencing of
the product to ensure the correct sequence was being amplified (Figure
1c, page 9) and generation of positive controls for use in the qPCR. 
During all qPCR programs a melt curve was included as a final stage
after amplification; this involves measuring fluorescence continuously
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Why is it so important that the pharma industry and
diagnostic companies adopt RT-qPCR?
RT-qPCR has become the gold standard for RNA quantification.
Following the whole transcriptome RNA-seq approach, RT-qPCR
enables precise validation of differential gene expression information
on selected genes. It is widely used by pharma to discover and monitor
biomarkers in disease. In addition, RNA-virus diagnosis by RT-qPCR
offers an accurate way of detecting pathogens and quantifying the viral
load. Used as a companion diagnostic test, this technique can monitor
the efficacy of therapeutic treatments against a targeted virus, cancer
or chronic disease.
How do your products compare to 
others on the market?
The industry requires rapid, sensitive and accurate detection of any
RNA. Takara Clontech offers a unique, complete product line for 
one- and two-step RT-qPCR based on best-in-class enzymes.
PrimeScript RTase was developed to express high strand-displacement
activity, efficient cDNA synthesis up to 13kb and low error rates.
Combining such a unique enzyme with the powerful ExTaq HS
polymerase and a thermostable RNase H ensures accurate RNA
quantification by removing any inhibition of PCR. This ultimately results
in increased sensitivity, easy setup and less time expended, compared
with competitors’ solutions.
There is currently a lack of consensus in the industry 
on how best to perform and interpret qPCR experiments.
What are you doing to tackle this issue?
Obtaining data from RT-qPCR is easy; interpreting them requires taking
a step back from the experiment and identifying the bottlenecks. 
Our customers can rely on a team of experts in the setup and
troubleshooting of RT-qPCR experiments. Takara Clontech produces
consistent reagents knowing the requirements of the technology, 
e.g., by providing a RT reagent with a fast and efficient gDNA removal
step, which avoids the quantification of contaminant genomic DNA; by
including a special solution for accurate dilution of cDNA; and 
by addressing the specificity problems of SYBR detection with different
reagents versions. As such we support researchers to help them
produce reliable RNA analysis tools for diagnostic, prognostic and
therapeutic validation of candidates.
RT-qPCR technology is a field that is constantly 
evolving – can you keep up?
Our motto is: That’s GOOD Science!™. Our enzymologists are striving to
constantly improve enzyme-buffer performance and kit formulation for
gene expression analysis, anticipating commonly encountered issues
and changing requirements of the technology. Production is performed
under strict QC within our ISO certified facilities. Our products are
already included in many CE-IVD or FDA-approved kits. 
European Pharmaceutical Review interviews François-Xavier Sicot, PhD, Senior Product Manager at 
Takara Bio Europe, about his views on Reverse Transcription qPCR (RT-qPCR).
Q&A
as the temperature is increased slowly from 65 to 95°C. SYBR green dye
is initially bound by the double stranded DNA products which are the
result of amplification; with the slow increase in temperature a point is
reached at which the secondary structure denatures and the DNA
strands separate, resulting in a sharp decrease in fluorescence as the
SYBR green dissociates from the DNA. The temperature at which this
occurs is specific to each product, allowing determination of whether
the sample products are identical to that of positive or negative
controls. Figure 1d (page 9) provides an example of the melting
temperature (designated Tm) graphic from the albumin qPCR assay,
indicating that all products (including positive control) have the same
Tm. Negative controls (illustrated as the flat blue lines along the bottom
of the trace) indicate that any small amount of product present differs
from that seen in the samples and positive controls. The range of Tms
observed in this assay is small, with good efficiency and small errors 
for the standard curve (a one in 10 serial dilution of the cloned PCR
product over five orders of magnitude) (Figure 1e, page 9). 
The efficiency, calculated from the slope of the standard curve,
indicates that the amount of product detected in this assay increases
by 2.003 with every cycle. Since an efficiency of exactly two, the
theoretical value for qPCR, would indicate an exact doubling of product
with each cycle, this assay is working well. For all assays used in this
analysis of cell lines, efficiency values were as close as possible to two.
If initial attempts showed efficiency significantly below this,
optimisation of primer and template concentrations and annealing
temperature were performed. Suitable reference genes for
normalisation of the data were determined using GeNorm software18,
and primer sets purchased from PrimerDesign (Southampton, UK)
which were TOP1 and GAPDH for Huh7 cells, and hATP5b and GAPDH for
HepG2 cells. Numerous studies19-22 have indicated that many commonly
used reference genes vary between tissue and sample types; therefore
the MIQE guidelines suggest that better quality data are obtained using
more than one reference gene.
Cell lines were compared before and following DMSO treatment as a
proposed tool to enhance hepatocyte differentiation and compared to
expression in a sample of whole liver cDNA comprised of a pool of three
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human liver samples (37 year old Caucasian male, 64 year old Caucasian
male, 70 year old Caucasian female; purchased from PrimerDesign, UK).
Albumin and alpha-feto protein (AFP) mRNA expression were
determined to inform the relative hepatocyte-like differentiation of
cells. Albumin expression is indicative of an adult-like differentiation
comparable to hepatocytes in vivo, while AFP expression is indicative of
de-differentiated foetal-like hepatocytes23,24. A slight increase in albumin
mRNA expression following DMSO treatment
was observed for both HepG2 and Huh7 cells,
but this was much lower than the levels in liver
(Figure 2a). Reported albumin mRNA expression
in HepaRG cells ranged from close to liver to
similar to that in HepG2 and Huh7 cells12,14,25
(Figure 2a). AFP mRNA should decrease with
differentiation; this was observed following
DMSO treatment of Huh7 cells but not within HepG2 cells (Figure 2b).
HepaRG cells are reported to express AFP at very low levels, similar to
those in the liver in vivo12,14,25.
Results for two other genes of interest are illustrated in Figure 2;
the multidrug resistance protein 1 (MDR1 or P-gp) transporter and the
key drug-metabolising enzyme CYP3A426. MDR1 is expressed extensively
in the liver and increased expression can be associated with drug
resistance in tumours; a high level of expression may lead to erroneous
results in drug testing with cell models. HepG2 cells illustrated
increased levels of MDR1 expression compared with liver under basal
conditions, which was not reduced by DMSO treatment. MDR1
expression in Huh7 was lower than that found in liver and again was not
altered by DMSO treatment. Reported expression of MDR1 in HepaRG
cells varied between levels similar to those in HepG2 and comparable to
liver14,27-29. Critically, there was a high level of expression of CYP3A4 
in liver, but this was not replicated in any of the cell lines, with or
without treatment with DMSO (Figure 2d)12,14,25,28,29.
At face value, while the cell lines under consideration here do not
provide adequate models for differentiated adult hepatocytes, the data
suggest that HepaRG may be the closest approximation. However, the
results from these qPCR comparisons require
some more detailed examination. Ceelen 
and colleagues30 discussed HepaRG qPCR data
and its compliance with the MIQE guidelines.
They noted that many of the previous
publications analysing mRNA levels in HepaRG
cells utilised 18S rRNA as a reference gene.
Upon conducting analysis of the suitability of
reference genes in HepaRG cells with three different algorithms,
including the GeNorm software, 18S rRNA was ranked among the least
suitable by all three algorithms. Ceelen et al.31 further analysed more
than 20 previously published studies of qPCR in HepaRG cells, revealing
that MIQE recommendations concerning appropriate housekeeping
gene selection had not been taken into consideration. Thus, forming
definitive conclusions on the superiority of HepaRG cells based 
on the evidence of such poorly controlled qPCR data alone is 
perhaps questionable.
Conclusion
Quantitative PCR analysis of cell models is a powerful tool, if applied
robustly. It has identified that neither HepG2 nor Huh7 cells are ideal
12 European Pharmaceutical Review VOLUME 20 ISSUE 3 2015
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Figure 2: mRNA expression, shown relative to that in the liver, of basal and DMSO-related HepG2 and Huh7 cells assessed by qPCR for albumin (a), AFP (b), MDR1 (c) and
CYP3A4 (d). A minimum of N=3 experiments were performed for HepG2 and Huh7 results. A literature search was performed to obtain data for levels of mRNA expression in
the HepaRG cell line, with the highest (purple) and lowest (green) values shown
A qPCR assay would provide a
relatively inexpensive, high-throughput
means of determining the differentiation
state of cells 
Even small air currents can stop your balance from settling. But 
the breakthrough weighing pan – SmartPan™ – on XPE precision 
balances combats such influences to deliver your results up to twice 
as fast, and improve repeatability up to two-fold, even in a fume hood.
Our brand new white paper presents empirical test data demonstrating 
how the effects of air currents can be dramatically reduced.
Not Even a Gust of Wind 
Will Affect Your Weighing
 www.mt.com/smartpan
Free download:
models to represent differentiated hepatocytes, with or without
treatment with DMSO. HepaRG cells appear to provide a more suitable
level of hepatocyte differentiation. However, in addition to ensuring
appropriate application of qPCR standards, for any cell model to be
validated fully also requires subsequent protein and functional
characteristics to be determined. Once this has been achieved, and 
co-ordination between changes at the mRNA and protein/functional
levels established, a qPCR assay would provide a relatively inexpensive,
high-throughput means of determining the differentiation state of cells
and thus their suitability as a model in drug discovery applications. 
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University. A very enthusiastic biology teacher and a
subsequent degree in Human Genetics combined to spark an
interest in human biology, which eventually led to a PhD
investigating hepatic cell models. Since graduating from her
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References
1. Saiki RK, Bugawan TL, Horn GT, Mullis KB, Erlich HA. Analysis of enzymatically
amplified beta-globin and HLA-DQ alpha DNA with allele-specific oligonucleotide probes.
Nature. 1986;324(6093):163-6
2. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time
quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (San Diego, Calif).
2001;25(4):402-8
3. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE
guidelines: minimum information for publication of quantitative real-time PCR
experiments. Clinical chemistry. 2009;55(4):611-22
4. Orloff J, Douglas F, Pinheiro J, Levinson S, Branson M, Chaturvedi P, et al.
The future of drug development: advancing clinical trial design. Nat Rev Drug Discov.
2009;8(12):949-57
5. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug
development costs. Journal of Health Economics. 2003;22(2):151-85
6. Westerink WMA, Schoonen WGEJ. Cytochrome P450 enzyme levels in HepG2 cells and
cryopreserved primary human hepatocytes and their induction in HepG2 cells. Toxicology
in Vitro. 2007;21(8):1581-91
7. Elizondo G, Medina-Diaz IM. Induction of CYP3A4 by 1alpha,25-dyhydroxyvitamin D3 in
HepG2 cells. Life Sci. 2003;73(2):141-9
8. Sivertsson L, Ek M, Darnell M, Edebert I, Ingelman-Sundberg M, Neve EPA. CYP3A4
Catalytic Activity Is Induced in Confluent Huh7 Hepatoma Cells. Drug Metabolism and
Disposition. 2010;38(6):995-1002
9. Olsavsky KM, Page JL, Johnson MC, Zarbl H, Strom SC, Omiecinski CJ. Gene
expression profiling and differentiation assessment in primary human hepatocyte
cultures, established hepatoma cell lines, and human liver tissues. Toxicol Appl
Pharmacol. 2007;222(1):42-56
10. Westerink WMA, Schoonen WGEJ. Phase II enzyme levels in HepG2 cells and
cryopreserved primary human hepatocytes and their induction in HepG2 cells.
Toxicology in Vitro. 2007;21(8):1592-602
11. Hewitt NJ, Hewitt P. Phase I and II enzyme characterization of two sources of HepG2 cell
lines. Xenobiotica. 2004;34(3):243-56
12. Aninat C, Piton A, Glaise D, Le Charpentier T, Langouet S, Morel F, et al. Expression of
cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma
HepaRG cells. Drug metabolism and disposition: the biological fate of chemicals.
2006;34(1):75-83
13. Kanebratt KP, Andersson TB. HepaRG Cells as an In Vitro Model for Evaluation of
Cytochrome P450 Induction in Humans. Drug metabolism and disposition: the biological
fate of chemicals. 2007:dmd.107.017418
14. Kanebratt KP, Andersson TB. Evaluation of HepaRG Cells as an In Vitro Model for
Human Drug Metabolism Studies. Drug metabolism and disposition: the biological fate
of chemicals. 2008:dmd.107.020016
15. Hart SN, Li Y, Nakamoto K, Subileau E-a, Steen D, Zhong X-b. A Comparison of Whole
Genome Gene Expression Profiles of HepaRG Cells and HepG2 Cells to Primary Human
Hepatocytes and Human Liver Tissues. Drug Metabolism and Disposition.
2010;38(6):988-94
16. Jennen DGJ, Magkoufopoulou C, Ketelslegers HB, van Herwijnen MHM, Kleinjans JCS,
van Delft JHM. Comparison of HepG2 and HepaRG by Whole-Genome Gene
Expression Analysis for the Purpose of Chemical Hazard Identification. Toxicol Sci.
2010;115(1):66-79
17. Le Vee M, Lecureur V, Moreau A, Stieger B, Fardel O. Differential regulation of drug
transporter expression by hepatocyte growth factor in primary human hepatocytes. Drug
metabolism and disposition: the biological fate of chemicals. 2009;37(11):2228-35
18. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate
normalization of real-time quantitative RT-PCR data by geometric averaging of multiple
internal control genes. Genome Biol. 2002;3(7):RESEARCH0034
19. Lanoix D, Lacasse AA, St-Pierre J, Taylor SC, Ethier-Chiasson M, Lafond J, et al.
Quantitative PCR pitfalls: the case of the human placenta. Molecular biotechnology.
2012;52(3):234-43
20. Aerts JL, Gonzales MI, Topalian SL. Selection of appropriate control genes to
assess expression of tumor antigens using real-time RT-PCR. BioTechniques.
2004;36(1):84-6, 8, 90-1
21. McCurley AT, Callard GV. Characterization of housekeeping genes in zebrafish: male-
female differences and effects of tissue type, developmental stage and chemical treatment.
BMC molecular biology. 2008;9:102
22. Gu YR, Li MZ, Zhang K, Chen L, Jiang AA, Wang JY, et al. Evaluation of endogenous
control genes for gene expression studies across multiple tissues and in the specific sets of
fat- and muscle-type samples of the pig. Journal of animal breeding and genetics =
Zeitschrift fur Tierzuchtung und Zuchtungsbiologie. 2011;128(4):319-25
23. Snykers S, De Kock J, Vanhaecke T, Rogiers V. Differentiation of neonatal rat epithelial
cells from biliary origin into immature hepatic cells by sequential exposure to hepatogenic
cytokines and growth factors reflecting liver development. Toxicology in Vitro.
2007;21(7):1325-31
24. Page JL, Johnson MC, Olsavsky KM, Strom SC, Zarbl H, Omiecinski CJ. Gene
expression profiling of extracellular matrix as an effector of human hepatocyte phenotype
in primary cell culture. Toxicol Sci. 2007;97(2):384-97
25. Hoekstra R, Nibourg GA, van der Hoeven TV, Ackermans MT, Hakvoort TB, van Gulik
TM, et al. The HepaRG cell line is suitable for bioartificial liver application. The
international journal of biochemistry & cell biology. 2011;43(10):1483-9
26. Chan LM, Lowes S, Hirst BH. The ABCs of drug transport in intestine and liver: efflux
proteins limiting drug absorption and bioavailability. European journal of pharmaceutical
sciences : official journal of the European Federation for Pharmaceutical Sciences.
2004;21(1):25-51
27. Le Vee M, Jigorel E, Glaise D, Gripon P, Guguen-Guillouzo C, Fardel O. Functional
expression of sinusoidal and canalicular hepatic drug transporters in the differentiated
human hepatoma HepaRG cell line. European Journal of Pharmaceutical Sciences.
2006;28(1-2):109-17
28. Gerets HH, Tilmant K, Gerin B, Chanteux H, Depelchin BO, Dhalluin S, et al.
Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the
mRNA level and CYP activity in response to inducers and their predictivity for the
detection of human hepatotoxins. Cell biology and toxicology. 2012;28(2):69-87
29. Antherieu S, Chesne C, Li R, Camus S, Lahoz A, Picazo L, et al. Stable expression,
activity, and inducibility of cytochromes P450 in differentiated HepaRG cells. Drug
metabolism and disposition: the biological fate of chemicals. 2010;38(3):516-25
30. Ceelen L, De Spiegelaere W, David M, De Craene J, Vinken M, Vanhaecke T, et al.
Critical selection of reliable reference genes for gene expression study in the HepaRG cell
line. Biochemical pharmacology. 2011;81(10):1255-61
31. Ceelen L, De Craene J, De Spiegelaere W. Evaluation of normalization strategies used in
real-time quantitative PCR experiments in HepaRG cell line studies. Clinical chemistry.
2014;60(3):451-4
